Is Vonoprazan Better Than a PPI for Severe Esophagitis?
At a Glance
For severe Grade C or D erosive esophagitis, vonoprazan may heal the esophagus faster and more reliably than some PPIs, while PPIs remain standard for mild disease. Persistent symptoms require testing before changing treatment.
If you have severe erosive esophagitis that is not healing on standard medications, vonoprazan is an approved alternative that may heal your esophagus more effectively than traditional options [1]. While traditional proton pump inhibitors (PPIs) like omeprazole or lansoprazole remain the standard first choice for mild esophageal damage, vonoprazan provides stronger, more sustained 24-hour acid control [2]. Updated clinical guidelines from organizations like the American Gastroenterological Association (AGA) now include vonoprazan as an option for patients with severe (Grade C or D) esophagitis, or for those whose esophageal damage has objectively not healed after standard PPI treatment [3].
How Vonoprazan Works Differently
Traditional medications (like omeprazole) are PPIs, which permanently bind to active acid pumps in the stomach. Vonoprazan belongs to a newer class called potassium-competitive acid blockers (PCABs). PCABs block the stomach’s acid pumps directly by reversibly competing with potassium. This different mechanism gives PCABs a few distinct traits:
- Faster onset: PPIs require active pumps and can take a few days to build up their full effect. Vonoprazan begins blocking acid pumps rapidly, offering strong acid suppression on the very first day [2].
- Easier timing: Most delayed-release PPIs work best when taken 30 to 60 minutes before a meal, requiring strict adherence to a daily schedule [4]. Vonoprazan can be taken with or without food.
- Better nighttime control: Because of the way PCABs interact with the acid pumps, vonoprazan provides much more sustained 24-hour and nighttime acid control compared to traditional PPIs [5].
Healing Severe vs. Mild Esophagitis
During an endoscopy, doctors grade erosive esophagitis from Grade A (mildest) to Grade D (most severe). “Healing” means the physical mucosal damage to the esophageal lining is repaired—which is different from simply feeling symptom relief.
For mild (Grade A or B) esophagitis, research shows that traditional PPIs and vonoprazan heal the esophagus at similar rates [6]. Because PPIs are widely available, highly effective, and generally less expensive, they remain the standard first choice for mild disease [3].
However, for severe (Grade C or D) esophagitis, a large clinical trial showed that a 20 mg daily dose of vonoprazan healed severe damage faster and more effectively than a 30 mg dose of lansoprazole (a standard PPI) [1]. By week 2, the healing rate for severe esophagitis was 17.6 percentage points higher for patients taking vonoprazan [1]. By week 8, overall healing was achieved in 92.9% of those on vonoprazan compared to 84.6% on lansoprazole [1].
What if My Esophagitis Isn’t Healing?
If you continue to have heartburn or pain on a traditional PPI, it does not automatically mean your esophagitis is “refractory” (resistant to treatment). Persistent symptoms do not always mean you still have persistent acid damage [7].
Before diagnosing refractory esophagitis, your doctor will likely want to confirm that you have been taking your current PPI exactly as directed (usually 30–60 minutes before a meal) [4]. If your medication is optimized and symptoms persist, your doctor may recommend a repeat endoscopy or acid monitoring. This testing is crucial to confirm whether acid damage is actually still present, or if your symptoms are being caused by something else, like a hiatal hernia, functional heartburn, or a condition called eosinophilic esophagitis [7].
If tests confirm that your esophagus is genuinely not healing despite taking a PPI correctly, your doctor may suggest doubling your PPI dose, referring you to a specialist for anti-reflux procedures, or switching to a PCAB. Observational studies of patients with objectively confirmed PPI-refractory esophagitis have shown significant healing rates (between 88% and 91%) within 4 to 8 weeks after switching to vonoprazan [8].
Long-Term Maintenance & Follow-Up
Severe (Grade C or D) esophagitis often requires long-term or even indefinite acid suppression to prevent the damage from returning [9]. In a 24-week clinical trial, vonoprazan proved superior to lansoprazole in preventing the relapse of severe erosive esophagitis [10].
It is also highly recommended that patients with severe esophagitis have a follow-up endoscopy after completing their initial healing treatment [11]. This allows the doctor to visually confirm the physical damage is gone and check the underlying tissue for complications like Barrett’s esophagus, which can initially be hidden by severe inflammation.
Safety and Urgent Warning Signs
Like all medications, vonoprazan has potential side effects and interactions. Discuss your full medical history with your doctor or pharmacist, especially if you have liver or kidney issues, or take other medications, so they can check for safety issues and drug interactions.
When to Seek Immediate Care: Regardless of which medication you take, you should contact a doctor immediately or seek urgent care if you experience “red flag” symptoms. These include:
- Food getting stuck in your throat or chest
- Painful or progressive difficulty swallowing
- Vomiting blood or material that looks like coffee grounds
- Black, tarry stools
- Unexplained weight loss or anemia
- Severe or new chest pain
Common questions in this guide
Is vonoprazan more effective than a PPI for severe erosive esophagitis?
How does vonoprazan differ from a traditional PPI?
What should I do if my esophagitis is not healing while I take a PPI?
Do I need another endoscopy after treatment for severe esophagitis?
Will severe erosive esophagitis require long-term acid-suppressing treatment?
Which symptoms of erosive esophagitis require urgent medical care?
Questions to Ask Your Doctor
Curated prompts to bring to your next appointment.
- 1.Does my latest endoscopy show mild (Grade A or B) or severe (Grade C or D) esophagitis, and do I need a repeat endoscopy to confirm it has healed?
- 2.If my esophagitis hasn't healed, should we optimize my PPI dose, switch to a medication like vonoprazan, or test for other causes of my symptoms?
- 3.What are the long-term maintenance plans for my specific grade of esophagitis, and what are the risks of long-term therapy?
- 4.Are there any interactions between vonoprazan and my other medications, or medical conditions (like kidney/liver issues) I should be aware of?
- 5.Does my insurance require prior authorization showing I've failed traditional PPI therapy before they will cover a PCAB?
Questions For You
Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.
Related questions
References
References (11)
- 1
Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Laine L, DeVault K, Katz P, et al.
Gastroenterology 2023; (164(1)):61-71 doi:10.1053/j.gastro.2022.09.041.
PMID: 36228734 - 2
Pharmacodynamics and Pharmacokinetics of the Potassium-Competitive Acid Blocker Vonoprazan and the Proton Pump Inhibitor Lansoprazole in US Subjects.
Laine L, Sharma P, Mulford DJ, et al.
The American journal of gastroenterology 2022; (117(7)):1158-1161 doi:10.14309/ajg.0000000000001735.
PMID: 35294415 - 3
AGA Clinical Practice Update on Integrating Potassium-Competitive Acid Blockers Into Clinical Practice: Expert Review.
Patel A, Laine L, Moayyedi P, Wu J
Gastroenterology 2024; (167(6)):1228-1238 doi:10.1053/j.gastro.2024.06.038.
PMID: 39269391 - 4
Vietnam Association of Gastroenterology (VNAGE) guideline on the management of gastroesophageal reflux disease.
Dao HV, Mai BH, Dao LV, et al.
Frontiers in medicine 2026; (13()):1890726 doi:10.3389/fmed.2026.1890726.
PMID: 42609230 - 5
Night-time gastric acid suppression by tegoprazan compared to vonoprazan or esomeprazole.
Yang E, Kim S, Kim B, et al.
British journal of clinical pharmacology 2022; (88(7)):3288-3296 doi:10.1111/bcp.15268.
PMID: 35146797 - 6
Vonoprazan is superior to lansoprazole for healing of severe but not mild erosive esophagitis: A systematic review with meta-analysis of randomized controlled trials.
Simadibrata DM, Lesmana E, Fass R
Journal of gastroenterology and hepatology 2024; (39(6)):988-999 doi:10.1111/jgh.16486.
PMID: 38353152 - 7
Refractory Gastroesophageal Reflux Disease: Diagnosis and Management.
Davis TA, Gyawali CP
Journal of neurogastroenterology and motility 2024; (30(1)):17-28 doi:10.5056/jnm23145.
PMID: 38173155 - 8
A systematic review and meta-analysis of the efficacy of vonoprazan for proton pump inhibitor-resistant gastroesophageal reflux disease.
Simadibrata DM, Lesmana E, Fass R
Journal of gastroenterology and hepatology 2024; (39(5)):796-805 doi:10.1111/jgh.16475.
PMID: 38263507 - 9
2025 Focused Update of the Seoul Consensus on Gastroesophageal Reflux Disease: Evidence-based Recommendations on Acid Suppressive Therapy.
Huh CW, Chang JW, Son NH, et al.
Journal of neurogastroenterology and motility 2026; (32(1)):7-18 doi:10.5056/jnm25128.
PMID: 41017123 - 10
A systematic review with meta-analysis: Efficacy and safety of potassium-competitive acid blocker compared with proton pump inhibitor in the maintenance of healed erosive esophagitis.
Simadibrata DM, Lesmana E, Pratama MIA, et al.
JGH open : an open access journal of gastroenterology and hepatology 2024; (8(3)):e13053 doi:10.1002/jgh3.13053.
PMID: 38523708 - 11
Recent effectiveness of proton pump inhibitors for severe reflux esophagitis: the first multicenter prospective study in Japan.
Mizuno H, Matsuhashi N, Sakaguchi M, et al.
Journal of clinical biochemistry and nutrition 2015; (57(3)):233-8 doi:10.3164/jcbn.14-144.
PMID: 26566310
This page is for informational purposes only and does not constitute medical advice. Your gastroenterologist or pharmacist can help determine the safest treatment, follow-up testing, and long-term plan for your condition.
Get notified when new evidence is published on peptic esophagitis.
We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.